An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) is set to present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The CEO, Robert Connelly, will be presenting the clinical-stage biotechnology company's pipeline of novel immunotherapies for cancer treatment. The presentation will be available via live webcast and on-demand for 90 days after the event.
Positive
None.
Negative
None.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.
A live webcast of the presentation will be accessible under “Events” in the Investors section of Elicio’s website and will be available on-demand for 90 days following the event.
About Elicio Therapeutics Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.
Media Contact Kristin Politi LifeSci Communications kpoliti@lifescicomms.com 646-876-4783
When is Elicio Therapeutics presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?
Elicio Therapeutics will present at the conference on February 13, 2024 at 12:40 PM ET.
Who will be presenting at the conference?
Robert Connelly, the CEO of Elicio Therapeutics, will be presenting at the conference.
What is the ticker symbol for Elicio Therapeutics?
The ticker symbol for Elicio Therapeutics is ELTX.
Where can I access the webcast of the presentation?
The webcast will be accessible under 'Events' in the Investors section of Elicio’s website and will be available on-demand for 90 days following the event.
elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. by combining expertise in materials science and immunology, elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. the elicio amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. this substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. elicio's lead amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. elicio was founded to expand and apply the ground-breaking amphiphile technology invented and developed in the labs of darrell